Conclusion
The results suggest that low dose weekly MTX therapy might be tolerable and have a beneficial effect on the treatment of patients with progressive NB since it prevented the progression of the neuropsychiatric manifestations by markedly decreasing CSF IL-6 levels.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Inaba, G., 1989, Behçet’s disease. In: Handbook of Clinical Neurology (R.R. McKendall, ed.), Elsevier, Amsterdam, pp. 593–610.
Hirohata, S., et al., 1997, Cerebrospinal fluid interleukin-6 in progressive neuro-Behçet’s syndrome. Clin. Immunol. Immunopathol. 82: 12–17.
Hirohata S., et al., 1998, Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet’s disease. J. Neurol Sci. 159: 181–185.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Kluwer Academic Publishers
About this chapter
Cite this chapter
Kikuchi, H., Aramaki, K., Hirohata, S. (2004). Low Dose MTX for Progressive Neuro-Behçet’s Disease. In: Zouboulis, C.C. (eds) Adamantiades-Behçet’s Disease. Advances in Experimental Medicine and Biology, vol 528. Springer, Boston, MA. https://doi.org/10.1007/0-306-48382-3_117
Download citation
DOI: https://doi.org/10.1007/0-306-48382-3_117
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-47757-7
Online ISBN: 978-0-306-48382-0
eBook Packages: Springer Book Archive